TrialFrontiers in immunology2022

Low-dose IL-2 improved clinical symptoms by restoring reduced regulatory T cells in patients with refractory rheumatoid arthritis: A randomized controlled trial.

Jia Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.